Bitaccess

bit.bio has commercialized a range of highly defined human iPSC-derived cells ("ioCells") used in research and drug discovery. Its proprietary opti‑ox™ technology enables deterministic programming of stem cells into any desired mature human cell type at scale. The company’s pipeline includes preclinical work toward next-generation cell therapies targeting cancer, neurodegeneration, autoimmune diseases, but no clinical-stage programs have been publicly disclosed as of June 2025. The company also operates a joint venture ("bit.bio discovery") focused on early-stage/preclinical drug target identification using advanced CRISPR/iPSC platforms.